Timothy Kieffer
Technik-/Wissenschafts-/F&E-Leiter bei FRACTYL HEALTH, INC.
Vermögen: - $ am 31.05.2024
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Harith Rajagopalan | M | 48 | 14 Jahre | |
| Jay Caplan | M | 63 | 14 Jahre | |
| Amy Schulman | F | 63 | 6 Jahre | |
| Kelly Barnes | F | 58 | 2 Jahre | |
| Jon Fitzgerald | M | - | 12 Jahre | |
| Marc Elia | M | 48 | 3 Jahre | |
| Ajay Royan | M | 45 | 10 Jahre | |
| Sarah S. Toomey | F | 50 | 2 Jahre | |
| Clive Meanwell | M | 67 | 3 Jahre | |
| Lisa Davidson | F | 58 | 9 Jahre | |
| Bill Bradley | M | 80 | 7 Jahre | |
| Samuel Conaway | M | - | - | |
| Allan Roger Will | M | 70 | 12 Jahre | |
| Len Rosberg | M | - | - | |
| Lisa Porter | M | 60 |
ViaCyte, Inc.
 ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | 2 Jahre |
| Helmut Giersiefen | M | 66 | - | |
| Kelly White | M | - | - |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Ian Smith | M | 58 |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | 3 Jahre |
| Fred Middleton | M | 74 |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | 23 Jahre |
| Brittany Bradrick | F | 54 |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | 1 Jahre |
| Mark Foletta | M | 63 |
ViaCyte, Inc.
ViaCyte, Inc. Pharmaceuticals: MajorHealth Technology ViaCyte, Inc. develops a stem cell-derived islet replacement therapy for the treatment of diabetes. Its development portfolio includes VC-01 product candidate, a cell replacement therapy for the treatment of type 1 diabetes. The company was founded in 1999 and is headquartered in San Diego, CA. | 9 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 21 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Timothy Kieffer
- Persönliches Netzwerk
